<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:38:11 -0700</creation_date>
  <update_date>2013-01-15 20:38:11 -0700</update_date>
  <accession>HMDBP10807</accession>
  <secondary_accessions>
    <accession>17082</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
  </synonyms>
  <gene_name>CHRM3</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05012</accession>
      <name>Olanzapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14331</accession>
      <name>Cevimeline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14339</accession>
      <name>Tramadol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14347</accession>
      <name>Succinylcholine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14425</accession>
      <name>Disopyramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14476</accession>
      <name>Ipratropium bromide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14484</accession>
      <name>Metixene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14486</accession>
      <name>Terfenadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14520</accession>
      <name>Trihexyphenidyl</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14527</accession>
      <name>Oxyphencyclimine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14531</accession>
      <name>Procyclidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13938</accession>
      <name>Promazine 5-sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14568</accession>
      <name>Hyoscyamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14578</accession>
      <name>Cyproheptadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14605</accession>
      <name>Methylscopolamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14639</accession>
      <name>Darifenacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14648</accession>
      <name>Tridihexethyl</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14658</accession>
      <name>Anisotropine Methylbromide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14712</accession>
      <name>Atropine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14760</accession>
      <name>Nicardipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14853</accession>
      <name>Paroxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14863</accession>
      <name>Homatropine Methylbromide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14867</accession>
      <name>Diphemanil Methylsulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14905</accession>
      <name>Benzquinamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14915</accession>
      <name>Propiomazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14947</accession>
      <name>Tropicamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15069</accession>
      <name>Maprotiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13972</accession>
      <name>N-Dealkylated tolterodine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15195</accession>
      <name>Oxybutynin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15202</accession>
      <name>Promethazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15217</accession>
      <name>Pilocarpine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15357</accession>
      <name>Mivacurium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15361</accession>
      <name>Diphenidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15369</accession>
      <name>Chlorprothixene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15430</accession>
      <name>Pancuronium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15431</accession>
      <name>Pipecuronium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15474</accession>
      <name>Methotrimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15479</accession>
      <name>Tiotropium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15530</accession>
      <name>Solifenacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15562</accession>
      <name>Isopropamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15591</accession>
      <name>Mepenzolate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15648</accession>
      <name>Fesoterodine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15654</accession>
      <name>Methacholine</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled amine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled acetylcholine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>muscarinic acetylcholine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Basolateral cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>1q43</locus>
    <gene_sequence>&gt;1773 bp
ATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG
ATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC
AATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG
GGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG
GTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG
ACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT
TCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC
TGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG
GTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA
ACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG
GCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG
TGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT
TATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG
CGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT
GTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG
AAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG
AAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT
GATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG
ACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC
ACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC
TTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT
CCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT
TCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA
GCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG
ATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC
ATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC
ATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC
CCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG
TGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT
TTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>590</residue_number>
    <molecular_weight>66127.4</molecular_weight>
    <theoretical_pi>9.62</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>68-91</region>
      <region>105-125</region>
      <region>143-164</region>
      <region>185-207</region>
      <region>230-252</region>
      <region>493-513</region>
      <region>528-547</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Muscarinic acetylcholine receptor M3
MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL
GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI
SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR
TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF
YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM
KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE
TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF
PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR
MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN
PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL</protein_sequence>
  </protein_properties>
  <genbank_protein_id>20302973</genbank_protein_id>
  <uniprot_id>P20309</uniprot_id>
  <uniprot_name>ACM3_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AF498917</genbank_gene_id>
  <genecard_id>CHRM3</genecard_id>
  <geneatlas_id>CHRM3</geneatlas_id>
  <hgnc_id>HGNC:1952</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ: Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.</reference_text>
      <pubmed_id>3443095</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bonner TI, Young AC, Brann MR, Buckley NJ: Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron. 1988 Jul;1(5):403-10.</reference_text>
      <pubmed_id>3272174</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kitano T, Liu YH, Ueda S, Saitou N: Human-specific amino acid changes found in 103 protein-coding genes.  Mol Biol Evol. 2004 May;21(5):936-44. Epub 2004 Mar 10.</reference_text>
      <pubmed_id>15014171</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1.  Nature. 2006 May 18;441(7091):315-21.</reference_text>
      <pubmed_id>16710414</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Speek M: Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol. 2001 Mar;21(6):1973-85.</reference_text>
      <pubmed_id>11238933</pubmed_id>
    </reference>
    <reference>
      <reference_text>Iverson HA, Fox D 3rd, Nadler LS, Klevit RE, Nathanson NM: Identification and structural determination of the M(3) muscarinic acetylcholine receptor basolateral sorting signal. J Biol Chem. 2005 Jul 1;280(26):24568-75. Epub 2005 May 2.</reference_text>
      <pubmed_id>15870063</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Cevimeline</name>
        <accession>HMDB14331</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cevimeline</name>
        <accession>HMDB14331</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cevimeline</name>
        <accession>HMDB14331</accession>
      </metabolite>
      <reference>
        <reference_text>Li X, Azlina A, Karabasil MR, Purwanti N, Hasegawa T, Yao C, Akamatsu T, Hosoi K: Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist. Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. Epub 2008 May       1.</reference_text>
        <pubmed_id>18450949</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cevimeline</name>
        <accession>HMDB14331</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A: Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther. 2001 Oct;299(1):255-60.</reference_text>
        <pubmed_id>11561087</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, Shigematsu A: The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg. 2002 Nov;95(5):1269-73, table of contents.</reference_text>
        <pubmed_id>12401609</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Succinylcholine</name>
        <accession>HMDB14347</accession>
      </metabolite>
      <reference>
        <reference_text>Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors.  Anesthesiology. 1998 Mar;88(3):744-50.</reference_text>
        <pubmed_id>9523819</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Succinylcholine</name>
        <accession>HMDB14347</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Yamamoto N, Ozaki T, Keida Y, Ohtsuka M, Goto T: A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9.</reference_text>
        <pubmed_id>10413067</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ipratropium bromide</name>
        <accession>HMDB14476</accession>
      </metabolite>
      <reference>
        <reference_text>Wellington K: Ipratropium bromide HFA.  Treat Respir Med. 2005;4(3):215-20; discussion 221-2.</reference_text>
        <pubmed_id>15987237</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metixene</name>
        <accession>HMDB14484</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metixene</name>
        <accession>HMDB14484</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51.</reference_text>
        <pubmed_id>10212017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trihexyphenidyl</name>
        <accession>HMDB14520</accession>
      </metabolite>
      <reference>
        <reference_text>Bognar IT, Altes U, Beinhauer C, Kessler I, Fuder H: A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):611-8.</reference_text>
        <pubmed_id>1635586</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trihexyphenidyl</name>
        <accession>HMDB14520</accession>
      </metabolite>
      <reference>
        <reference_text>Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR: Antagonist binding profiles of five cloned human muscarinic receptor subtypes.  J Pharmacol Exp Ther. 1991 Feb;256(2):727-33.</reference_text>
        <pubmed_id>1994002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trihexyphenidyl</name>
        <accession>HMDB14520</accession>
      </metabolite>
      <reference>
        <reference_text>Freedman SB, Beer MS, Harley EA: Muscarinic M1, M2 receptor binding. Relationship with functional efficacy.  Eur J Pharmacol. 1988 Oct 26;156(1):133-42.</reference_text>
        <pubmed_id>3208836</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxyphencyclimine</name>
        <accession>HMDB14527</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxyphencyclimine</name>
        <accession>HMDB14527</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxyphencyclimine</name>
        <accession>HMDB14527</accession>
      </metabolite>
      <reference>
        <reference_text>Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42.</reference_text>
        <pubmed_id>1426023</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxyphencyclimine</name>
        <accession>HMDB14527</accession>
      </metabolite>
      <reference>
        <reference_text>Schjelderup L, Kozlowski MR, Weissman A, Aasen AJ: Antimuscarinic effects of (R)- and (S)- oxyphencyclimine hydrochloride.  Pharm Res. 1988 Apr;5(4):236-7.</reference_text>
        <pubmed_id>3247303</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procyclidine</name>
        <accession>HMDB14531</accession>
      </metabolite>
      <reference>
        <reference_text>Myhrer T: Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology. 2010 Dec;31(6):629-38. Epub 2010 Jul 17.</reference_text>
        <pubmed_id>20624420</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Procyclidine</name>
        <accession>HMDB14531</accession>
      </metabolite>
      <reference>
        <reference_text>Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Schjelderup L, Aasen A, Lambrecht G, Christophe J: Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42.</reference_text>
        <pubmed_id>1426023</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hyoscyamine</name>
        <accession>HMDB14568</accession>
      </metabolite>
      <reference>
        <reference_text>Lysikova M, Havlas Z, Tucek S: Interactions between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem Res. 2001 Apr;26(4):383-94.</reference_text>
        <pubmed_id>11495349</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyproheptadine</name>
        <accession>HMDB14578</accession>
      </metabolite>
      <reference>
        <reference_text>Eltze M, Lambrecht G, Mutschler E: Cyproheptadine displays high affinity for muscarinic receptors but does not discriminate between receptor subtypes. Eur J Pharmacol. 1989 Dec 7;173(2-3):219-22.</reference_text>
        <pubmed_id>2625138</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylscopolamine</name>
        <accession>HMDB14605</accession>
      </metabolite>
      <reference>
        <reference_text>Sykes DA, Dowling MR, Charlton SJ: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol. 2009 Sep;76(3):543-51. Epub 2009 Jun 4.</reference_text>
        <pubmed_id>19498041</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylscopolamine</name>
        <accession>HMDB14605</accession>
      </metabolite>
      <reference>
        <reference_text>Voigtlander U, Johren K, Mohr M, Raasch A, Trankle C, Buller S, Ellis J, Holtje HD, Mohr K: Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol. 2003 Jul;64(1):21-31.</reference_text>
        <pubmed_id>12815157</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylscopolamine</name>
        <accession>HMDB14605</accession>
      </metabolite>
      <reference>
        <reference_text>Saito M, Kazuyama E, Shimizu S, Dimitriadis F, Kinoshita Y, Masuda E, Yamada S, Satoh K: Muscarinic receptors and their mRNAs in type 2 Goto-Kakizaki diabetic rat prostate. Prostate. 2010 Oct 1;70(14):1533-9.</reference_text>
        <pubmed_id>20687226</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Darifenacin</name>
        <accession>HMDB14639</accession>
      </metabolite>
      <reference>
        <reference_text>Bharucha AE, Ravi K, Zinsmeister AR: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G215-9. Epub 2010 Apr       15.</reference_text>
        <pubmed_id>20395537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Darifenacin</name>
        <accession>HMDB14639</accession>
      </metabolite>
      <reference>
        <reference_text>Bozkurt TE, Sahin-Erdemli I: M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. Epub 2009 Feb 5.</reference_text>
        <pubmed_id>19416629</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Darifenacin</name>
        <accession>HMDB14639</accession>
      </metabolite>
      <reference>
        <reference_text>Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin.  Clin Interv Aging. 2006;1(4):309-16.</reference_text>
        <pubmed_id>18046909</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Darifenacin</name>
        <accession>HMDB14639</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tridihexethyl</name>
        <accession>HMDB14648</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tridihexethyl</name>
        <accession>HMDB14648</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anisotropine Methylbromide</name>
        <accession>HMDB14658</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anisotropine Methylbromide</name>
        <accession>HMDB14658</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anisotropine Methylbromide</name>
        <accession>HMDB14658</accession>
      </metabolite>
      <reference>
        <reference_text>Bachrach WH: Clinical evaluation of anisotropine methyl bromide (valpin), an anticholinergic drug. Am J Dig Dis. 1972 Jun;17(6):505-12.</reference_text>
        <pubmed_id>4555460</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atropine</name>
        <accession>HMDB14712</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atropine</name>
        <accession>HMDB14712</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atropine</name>
        <accession>HMDB14712</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.</reference_text>
        <pubmed_id>2981533</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Homatropine Methylbromide</name>
        <accession>HMDB14863</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Homatropine Methylbromide</name>
        <accession>HMDB14863</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Homatropine Methylbromide</name>
        <accession>HMDB14863</accession>
      </metabolite>
      <reference>
        <reference_text>Li CK, Mitchelson F: The selective antimuscarinic action of stercuronium.  Br J Pharmacol. 1980 Oct;70(2):313-21.</reference_text>
        <pubmed_id>6893558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Homatropine Methylbromide</name>
        <accession>HMDB14863</accession>
      </metabolite>
      <reference>
        <reference_text>Gil L, Gomez LE, Duran I, Cueva-Rolon R: Muscarinic mediation of the urethro genital reflex in spinal cord-transected rats. Pharmacol Biochem Behav. 2000 Oct;67(2):215-23.</reference_text>
        <pubmed_id>11124384</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphemanil Methylsulfate</name>
        <accession>HMDB14867</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphemanil Methylsulfate</name>
        <accession>HMDB14867</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphemanil Methylsulfate</name>
        <accession>HMDB14867</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzquinamide</name>
        <accession>HMDB14905</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzquinamide</name>
        <accession>HMDB14905</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tropicamide</name>
        <accession>HMDB14947</accession>
      </metabolite>
      <reference>
        <reference_text>Betz AJ, McLaughlin PJ, Burgos M, Weber SM, Salamone JD: The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology (Berl). 2007 Oct;194(3):347-59. Epub 2007 Jun 27.</reference_text>
        <pubmed_id>17594079</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102.</reference_text>
        <pubmed_id>6297650</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9.</reference_text>
        <pubmed_id>7052344</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle.  J Pharm Pharmacol. 1981 Nov;33(11):720-4.</reference_text>
        <pubmed_id>6118411</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Schneider T, Fetscher C, Krege S, Michel MC: Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. Epub 2004 Feb 9.</reference_text>
        <pubmed_id>14769832</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, Armstrong SR, Steinfeld T, Hughes AD, Wilson RD, Jasper JR, Mammen M, Hegde SS: Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol. 2009 Mar 1;605(1-3):145-52. Epub 2009 Jan 10.</reference_text>
        <pubmed_id>19168050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Sellers DJ, Yamanishi T, Chapple CR, Couldwell C, Yasuda K, Chess-Williams R: M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro. J Auton Pharmacol. 2000 Jun;20(3):171-6.</reference_text>
        <pubmed_id>11193006</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Baldwin CM, Keating GM: Transdermal oxybutynin.  Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008.</reference_text>
        <pubmed_id>19275276</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. Epub 2009 May 13.</reference_text>
        <pubmed_id>19446545</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27.</reference_text>
        <pubmed_id>20590605</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Oki T, Kageyama A, Takagi Y, Uchida S, Yamada S: Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. J Urol. 2007 Feb;177(2):766-70.</reference_text>
        <pubmed_id>17222678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Maruyama S, Oki T, Otsuka A, Shinbo H, Ozono S, Kageyama S, Mikami Y, Araki I, Takeda M, Masuyama K, Yamada S: Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006 Jan;175(1):365-9.</reference_text>
        <pubmed_id>16406943</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting.  J Perianesth Nurs. 2002 Dec;17(6):364-76.</reference_text>
        <pubmed_id>12476402</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pilocarpine</name>
        <accession>HMDB15217</accession>
      </metabolite>
      <reference>
        <reference_text>Sykes DA, Dowling MR, Charlton SJ: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol. 2009 Sep;76(3):543-51. Epub 2009 Jun 4.</reference_text>
        <pubmed_id>19498041</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pilocarpine</name>
        <accession>HMDB15217</accession>
      </metabolite>
      <reference>
        <reference_text>Figueroa KW, Griffin MT, Ehlert FJ: Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther. 2009 Jan;328(1):331-42. Epub 2008 Sep 29.</reference_text>
        <pubmed_id>18824613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9.</reference_text>
        <pubmed_id>2329499</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria.  Fundam Clin Pharmacol. 1990;4(2):147-58.</reference_text>
        <pubmed_id>2141000</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mivacurium</name>
        <accession>HMDB15357</accession>
      </metabolite>
      <reference>
        <reference_text>Habre W, Adamicza A, Lele E, Novak T, Sly PD, Petak F: The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906.</reference_text>
        <pubmed_id>19020136</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenidol</name>
        <accession>HMDB15361</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenidol</name>
        <accession>HMDB15361</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenidol</name>
        <accession>HMDB15361</accession>
      </metabolite>
      <reference>
        <reference_text>Braverman AS, Tallarida RJ, Ruggieri MR Sr: Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol. 2002 Sep;283(3):R663-8.</reference_text>
        <pubmed_id>12185001</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenidol</name>
        <accession>HMDB15361</accession>
      </metabolite>
      <reference>
        <reference_text>Varoli L, Angeli P, Burnelli S, Marucci G, Recanatini M: Synthesis and antagonistic activity at muscarinic receptor subtypes of some 2-carbonyl derivatives of diphenidol. Bioorg Med Chem. 1999 Sep;7(9):1837-44.</reference_text>
        <pubmed_id>10530931</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diphenidol</name>
        <accession>HMDB15361</accession>
      </metabolite>
      <reference>
        <reference_text>Waelbroeck M, Camus J, Tastenoy M, Mutschler E, Strohmann C, Tacke R, Lambrecht G, Christophe J: Stereoselectivity of (R)- and (S)-hexahydro-difenidol binding to neuroblastoma M1, cardiac M2, pancreatic M3, and striatum M4 muscarinic receptors. Chirality. 1991;3(2):118-23.</reference_text>
        <pubmed_id>1863523</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorprothixene</name>
        <accession>HMDB15369</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pancuronium</name>
        <accession>HMDB15430</accession>
      </metabolite>
      <reference>
        <reference_text>Milchert M, Spassov A, Meissner K, Nedeljkov V, Lehmann C, Wendt M, Loster BW, Mazurkiewicz-Janik M, Gedrange T, Pavlovic D: Skeletal muscle relaxants inhibit rat tracheal smooth muscle tone in vitro.  J Physiol Pharmacol. 2009 Dec;60 Suppl 8:5-11.</reference_text>
        <pubmed_id>20400785</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pancuronium</name>
        <accession>HMDB15430</accession>
      </metabolite>
      <reference>
        <reference_text>Okanlami OA, Fryer AD, Hirshman C: Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61.</reference_text>
        <pubmed_id>8572329</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pipecuronium</name>
        <accession>HMDB15431</accession>
      </metabolite>
      <reference>
        <reference_text>Karpati E, Biro K, Kukorelli T: [Investigation of neuromuscular blocking agents at Richter Ltd].  Acta Pharm Hung. 2002;72(1):37-48.</reference_text>
        <pubmed_id>12426786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9.</reference_text>
        <pubmed_id>2870716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.</reference_text>
        <pubmed_id>2899826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiotropium</name>
        <accession>HMDB15479</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiotropium</name>
        <accession>HMDB15479</accession>
      </metabolite>
      <reference>
        <reference_text>Hansel TT, Barnes PJ: Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc). 2002 Sep;38(9):585-600.</reference_text>
        <pubmed_id>12582447</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiotropium</name>
        <accession>HMDB15479</accession>
      </metabolite>
      <reference>
        <reference_text>Barnes PJ: Tiotropium bromide.  Expert Opin Investig Drugs. 2001 Apr;10(4):733-40.</reference_text>
        <pubmed_id>11281822</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiotropium</name>
        <accession>HMDB15479</accession>
      </metabolite>
      <reference>
        <reference_text>Barnes PJ, Belvisi MG, Mak JC, Haddad EB, O'Connor B: Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 1995;56(11-12):853-9.</reference_text>
        <pubmed_id>10188785</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Solifenacin</name>
        <accession>HMDB15530</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Solifenacin</name>
        <accession>HMDB15530</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Solifenacin</name>
        <accession>HMDB15530</accession>
      </metabolite>
      <reference>
        <reference_text>Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S: Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. Epub 2009 May 13.</reference_text>
        <pubmed_id>19446545</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Solifenacin</name>
        <accession>HMDB15530</accession>
      </metabolite>
      <reference>
        <reference_text>Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A: AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010 Jul;160(5):1119-27.</reference_text>
        <pubmed_id>20590605</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Solifenacin</name>
        <accession>HMDB15530</accession>
      </metabolite>
      <reference>
        <reference_text>Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A, Mitchelson FJ, Burcher E: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009 Mar;328(3):893-9. Epub 2008 Nov 24.</reference_text>
        <pubmed_id>19029429</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Solifenacin</name>
        <accession>HMDB15530</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isopropamide</name>
        <accession>HMDB15562</accession>
      </metabolite>
      <reference>
        <reference_text>Eglen RM, Whiting RL: Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.</reference_text>
        <pubmed_id>3580704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isopropamide</name>
        <accession>HMDB15562</accession>
      </metabolite>
      <reference>
        <reference_text>Lane MA: Muscarinic cholinergic activation of mouse spleen cells cytotoxic to tumor cells in vitro. J Natl Cancer Inst. 1978 Sep;61(3):923-6.</reference_text>
        <pubmed_id>29133</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepenzolate</name>
        <accession>HMDB15591</accession>
      </metabolite>
      <reference>
        <reference_text>Tsai CS, Guede-Guina F, Smith MO, Vangah-Manda M, Ochillo RF: Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22.</reference_text>
        <pubmed_id>7623487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepenzolate</name>
        <accession>HMDB15591</accession>
      </metabolite>
      <reference>
        <reference_text>Tsai CS, Ochillo RF: Low temperature and muscarinic receptor activities.  Cryobiology. 1989 Oct;26(5):485-95.</reference_text>
        <pubmed_id>2791613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mepenzolate</name>
        <accession>HMDB15591</accession>
      </metabolite>
      <reference>
        <reference_text>Ochillo RF, Pugh DA: Atropine and mepenzolate mydriasis in rabbits: a comparative pupillographic analysis of two antimuscarinic agents. Res Commun Chem Pathol Pharmacol. 1982 Jun;36(3):503-6.</reference_text>
        <pubmed_id>7122991</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fesoterodine</name>
        <accession>HMDB15648</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fesoterodine</name>
        <accession>HMDB15648</accession>
      </metabolite>
      <reference>
        <reference_text>Nilvebrant L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol Toxicol. 2002 May;90(5):260-7.</reference_text>
        <pubmed_id>12076307</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methacholine</name>
        <accession>HMDB15654</accession>
      </metabolite>
      <reference>
        <reference_text>Liu PS, Chen YY, Feng CK, Lin YH, Yu TC: Muscarinic acetylcholine receptors present in human osteoblast and bone tissue.  Eur J Pharmacol. 2011 Jan 10;650(1):34-40. Epub 2010 Oct 1.</reference_text>
        <pubmed_id>20888332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methacholine</name>
        <accession>HMDB15654</accession>
      </metabolite>
      <reference>
        <reference_text>Fernandez-Rodriguez S, Broadley KJ, Ford WR, Kidd EJ: Increased muscarinic receptor activity of airway smooth muscle isolated from a mouse model of allergic asthma. Pulm Pharmacol Ther. 2010 Aug;23(4):300-7. Epub 2010 Mar 25.</reference_text>
        <pubmed_id>20347047</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methacholine</name>
        <accession>HMDB15654</accession>
      </metabolite>
      <reference>
        <reference_text>Liu T, Xie C, Chen X, Zhao F, Liu AM, Cho DB, Chong J, Yang PC: Role of muscarinic receptor activation in regulating immune cell activity in nasal mucosa. Allergy. 2010 Aug;65(8):969-77. Epub 2009 Nov 27.</reference_text>
        <pubmed_id>19951374</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methacholine</name>
        <accession>HMDB15654</accession>
      </metabolite>
      <reference>
        <reference_text>Gosens R, Rieks D, Meurs H, Ninaber DK, Rabe KF, Nanninga J, Kolahian S, Halayko AJ, Hiemstra PS, Zuyderduyn S: Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur Respir J. 2009 Dec;34(6):1436-43. Epub 2009 May 21.</reference_text>
        <pubmed_id>19460789</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
